Most Read Articles
Jairia Dela Cruz, 15 May 2019
Postmenopausal women with hormone receptor (HR)-positive breast cancer fare well with the addition of denosumab to aromatase inhibitors, with data from the phase III ABCSG-18 trial showing that the antiresorptive drug cuts the risk of fractures and confers a modest but significant improvement in disease-free survival with a favourable tolerability profile.
14 May 2019
At the recent GLYCEMIC GUARDIANS™ dinner symposium, three eminent speakers spoke on theindispensable role of medical nutrition therapy (MNT) in improving outcomes for patients with type2 diabetes (T2D).
Rachel Soon, 22 Jun 2018

“Every patient is unique.” For compounding pharmacist Sarah Abdullah, tailoring medicines to a person’s needs is nothing new after years of working in the clean rooms of Putrajaya Hospital. Now managing her own enterprise, the also-council member of the Malaysian Community Pharmacy Guild (MCPG) spoke to MIMS Pharmacist about her experiences in the field to date.

Pearl Toh, 24 Apr 2019
Adding high-dose vitamin D3 to standard chemotherapy for metastatic colorectal cancer (mCRC) may confer potential benefit to previously untreated patients in terms of progression-free survival (PFS) compared with supplemental standard-dose vitamin D3, suggests the phase II SUNSHINE* study.

Text message reminder improves HPV vaccination rate

Elaine Soliven
14 May 2019

The use of text messaging as a reminder for the next human papillomavirus (HPV) vaccine dose may help increase the rates of HPV vaccine series completion, according to a study presented at PAS* 2019 Meeting.

“HPV vaccine is a critical cancer-protecting vaccine; yet, only half of adolescents have received their needed doses … Even among those who start the series, only three-quarters get all the doses needed for protection,” said study lead author Associate Professor Melissa Stockwell from the Department of Pediatrics, Division of Pediatric Child and Adolescent Medicine at Columbia University Irving Medical Center in New York, US.

This AHRQ**-funded study consisted of 956 parents and their adolescents aged 9–17 years (50 percent female) who underwent a first HPV vaccine at four affiliated community clinics in US between December 2014 and 2016. Participants were randomized in a 1:1 ratio to receive either conventional text message (which stated the due date for the next HPV vaccine dose) or enhanced educational text message (which included educational information for the parent’s vaccine decision-making phase). The study’s primary outcome was the completion of two or three doses of HPV vaccine at 12 months. [PAS 2019, abstract 3335.6]

Participants who were enrolled in either text messaging groups showed a significantly higher completion rate of HPV vaccine compared with individuals who were screened but not eligible to enrol in the study (74.1 percent vs 45.2 percent; p<0.0001).

A significantly higher completion rate of HPV vaccine was also observed in both text messaging groups than those participants who had their first HPV vaccine within 3 years prior to this study (71.1 percent vs 34.8 percent; p<0.0001). “Finally, a population-wide effect was seen during the years of the study 2014–2016, above historical trends,” Stockwell said.

The completion rates of HPV vaccine series at 12 months were comparable between the conventional and educational text messaging groups (75.7 percent vs 72.4 percent).

“In this study, we found that text message vaccine reminders are a powerful, rapid, and scalable way to help encourage families to have adolescents complete their vaccine series,” Stockwell noted.

 

*PAS: Pediatric Academic Societies

**AHRQ: Agency for Healthcare Research & Quality

Digital Edition
Asia's trusted medical magazine for healthcare professionals. Get your MIMS Pharmacist - Malaysia digital copy today!
Sign In To Download
Editor's Recommendations
Most Read Articles
Jairia Dela Cruz, 15 May 2019
Postmenopausal women with hormone receptor (HR)-positive breast cancer fare well with the addition of denosumab to aromatase inhibitors, with data from the phase III ABCSG-18 trial showing that the antiresorptive drug cuts the risk of fractures and confers a modest but significant improvement in disease-free survival with a favourable tolerability profile.
14 May 2019
At the recent GLYCEMIC GUARDIANS™ dinner symposium, three eminent speakers spoke on theindispensable role of medical nutrition therapy (MNT) in improving outcomes for patients with type2 diabetes (T2D).
Rachel Soon, 22 Jun 2018

“Every patient is unique.” For compounding pharmacist Sarah Abdullah, tailoring medicines to a person’s needs is nothing new after years of working in the clean rooms of Putrajaya Hospital. Now managing her own enterprise, the also-council member of the Malaysian Community Pharmacy Guild (MCPG) spoke to MIMS Pharmacist about her experiences in the field to date.

Pearl Toh, 24 Apr 2019
Adding high-dose vitamin D3 to standard chemotherapy for metastatic colorectal cancer (mCRC) may confer potential benefit to previously untreated patients in terms of progression-free survival (PFS) compared with supplemental standard-dose vitamin D3, suggests the phase II SUNSHINE* study.